中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2012年
6期
554-558
,共5页
彭蘡%潘世扬%王芳%黄珮珺%徐婷%黄蕾%张丽霞%黎青%张红梅%徐建%秦雪君%韩月%徐娟%朱善军
彭蘡%潘世颺%王芳%黃珮珺%徐婷%黃蕾%張麗霞%黎青%張紅梅%徐建%秦雪君%韓月%徐娟%硃善軍
팽영%반세양%왕방%황패군%서정%황뢰%장려하%려청%장홍매%서건%진설군%한월%서연%주선군
肺肿瘤%癌%非小细胞肺%HSP70热休克蛋白质类%肿瘤标记%生物学%酶联免疫吸附测定
肺腫瘤%癌%非小細胞肺%HSP70熱休剋蛋白質類%腫瘤標記%生物學%酶聯免疫吸附測定
폐종류%암%비소세포폐%HSP70열휴극단백질류%종류표기%생물학%매련면역흡부측정
Lung neoplasms%Carcinoma%non-small-cell lung%HSP70 heat-shock proteins%Tumor markers%biological%Enzyme-linked immunosorbent assay
目的 评价血清中单抗NJ001相关靶抗原SP70能否成为检测非小细胞肺癌(NSCLC)的新型血清肿瘤标志物.方法 以SPC-A1为抗原免疫新西兰兔,制备多抗.用多抗包被微孔板,NJ001为一抗,酶标记的羊抗鼠抗体为标记抗体,建立双抗体夹心ELISA法,并优化实验条件；采用该法对2007年10月至2011年6月从南京医科大学第一附属医院收集的经病理确诊的175例肺癌(包括80例肺腺癌、70例肺鳞癌和25例小细胞肺癌)、25例肺良性疾病患者和300名健康体检者血清中SP70进行检测；同时与电化学发光法检测癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和角质蛋白19片段(CYFRA21-1)进行比较；各组间阳性率比较采用x2检验或Fisher确切概率法.结果 肺腺癌、肺鳞癌、小细胞肺癌和肺良性疾病组的阳性率分别为68.8％、51.4％、16.0％和12.0％,均明显高于健康体检组(7.3％)；NSCLC组(肺腺癌和肺鳞癌)阳性率高于小细胞肺癌组(60.7％υs 16.0％,x2 =17.23,P＜0.05)和肺良性疾病组(60.7％υs 12.0％,x2=20.41,P＜0.05)；68例有分期资料的NsCLC患者中,早期组(n=30)的阳性率达76.7％.另外,ELISA法对NSCLC患者SP70总检出率高于CEA、NSE和CYFRA21-1(32.7％、18.0％和37.3％),差异有统计学意义(60.7％υs32.7％x2=23.63,P＜0.05;60.7％υs18.0％,x2=57.22,P ＜0.05;60.7％υs37.3％,x2=16.34,P＜0.05).结论 NSCLC患者血清中SP70阳性检出率较高,SP70可能是潜在的用于诊断NSCLC的血清肿瘤标志物.
目的 評價血清中單抗NJ001相關靶抗原SP70能否成為檢測非小細胞肺癌(NSCLC)的新型血清腫瘤標誌物.方法 以SPC-A1為抗原免疫新西蘭兔,製備多抗.用多抗包被微孔闆,NJ001為一抗,酶標記的羊抗鼠抗體為標記抗體,建立雙抗體夾心ELISA法,併優化實驗條件；採用該法對2007年10月至2011年6月從南京醫科大學第一附屬醫院收集的經病理確診的175例肺癌(包括80例肺腺癌、70例肺鱗癌和25例小細胞肺癌)、25例肺良性疾病患者和300名健康體檢者血清中SP70進行檢測；同時與電化學髮光法檢測癌胚抗原(CEA)、神經元特異性烯醇化酶(NSE)和角質蛋白19片段(CYFRA21-1)進行比較；各組間暘性率比較採用x2檢驗或Fisher確切概率法.結果 肺腺癌、肺鱗癌、小細胞肺癌和肺良性疾病組的暘性率分彆為68.8％、51.4％、16.0％和12.0％,均明顯高于健康體檢組(7.3％)；NSCLC組(肺腺癌和肺鱗癌)暘性率高于小細胞肺癌組(60.7％υs 16.0％,x2 =17.23,P＜0.05)和肺良性疾病組(60.7％υs 12.0％,x2=20.41,P＜0.05)；68例有分期資料的NsCLC患者中,早期組(n=30)的暘性率達76.7％.另外,ELISA法對NSCLC患者SP70總檢齣率高于CEA、NSE和CYFRA21-1(32.7％、18.0％和37.3％),差異有統計學意義(60.7％υs32.7％x2=23.63,P＜0.05;60.7％υs18.0％,x2=57.22,P ＜0.05;60.7％υs37.3％,x2=16.34,P＜0.05).結論 NSCLC患者血清中SP70暘性檢齣率較高,SP70可能是潛在的用于診斷NSCLC的血清腫瘤標誌物.
목적 평개혈청중단항NJ001상관파항원SP70능부성위검측비소세포폐암(NSCLC)적신형혈청종류표지물.방법 이SPC-A1위항원면역신서란토,제비다항.용다항포피미공판,NJ001위일항,매표기적양항서항체위표기항체,건립쌍항체협심ELISA법,병우화실험조건；채용해법대2007년10월지2011년6월종남경의과대학제일부속의원수집적경병리학진적175례폐암(포괄80례폐선암、70례폐린암화25례소세포폐암)、25례폐량성질병환자화300명건강체검자혈청중SP70진행검측；동시여전화학발광법검측암배항원(CEA)、신경원특이성희순화매(NSE)화각질단백19편단(CYFRA21-1)진행비교；각조간양성솔비교채용x2검험혹Fisher학절개솔법.결과 폐선암、폐린암、소세포폐암화폐량성질병조적양성솔분별위68.8％、51.4％、16.0％화12.0％,균명현고우건강체검조(7.3％)；NSCLC조(폐선암화폐린암)양성솔고우소세포폐암조(60.7％υs 16.0％,x2 =17.23,P＜0.05)화폐량성질병조(60.7％υs 12.0％,x2=20.41,P＜0.05)；68례유분기자료적NsCLC환자중,조기조(n=30)적양성솔체76.7％.령외,ELISA법대NSCLC환자SP70총검출솔고우CEA、NSE화CYFRA21-1(32.7％、18.0％화37.3％),차이유통계학의의(60.7％υs32.7％x2=23.63,P＜0.05;60.7％υs18.0％,x2=57.22,P ＜0.05;60.7％υs37.3％,x2=16.34,P＜0.05).결론 NSCLC환자혈청중SP70양성검출솔교고,SP70가능시잠재적용우진단NSCLC적혈청종류표지물.
Objective To evaluate whether the protein SP70 could be used as a serum biomarker for the diagnosis of non-small cell lung cancer (NSCLC).Methods Polyclonal antibody was prepared by immunizing New Zealand rabbit with SPC-A1 cells.Sandwich ELISA was carried out by using newly-prepared polyclonal antibody(PcMb) coating assay plates,monoclonal antibody (McAb) NJ001 and HRP goat antimouse antibody as primary antibody and labeling antibody respectively.After optimizing the experiment conditions,serum from 175 lung cancer patients [ 80 NSCLC adenocarcinoma,70 NSCLC squamous carcinoma and 25 small cell lung cancer ( SCLC) ],25 benign lung disease ( BLD) patients and 300 healthy controls (HC) were examined.CEA,NSE,CYFRA21-1 were measured by ECLIA for comparison.Results Positive rates of NSCLC adenocarcinoma,NSCLC squamous carcinoma,SCLC and BLD were 68.8％,51.4％,16.0％ and 12.0％ respectively,obviously higher than that of HC (7.3％).NSCLC (adenocarcinoma,Squamous carcinoma) had significantly higher positive rate than SCLC (60.7％ υs 16.0％,x2 =17.23,P＜0.05)and BLD(60.7％ υs 12.0％,x2 =20.41,P ＜0.05).Among 68 NSCLC patients who had definite staging,positive rates at early stage ( Ⅰ/Ⅱ,n=30) reached up to 76.7％.Meanwhile,positive rates of CEA,NSE and CYFRA21-1 (32.7％,18.0％ and 37.3％) were significantly lower than the targeting antigen to McAb NJ001 in NSCLC(60.7％ υs 32.7％,x2 =23.63,P ＜0.05;60.7％υs18.0％,x2 =57.22,P＜0.05;60.7％ υs37.3％,x2=16.34,P＜0.05).Conclusions It showed high positive rates of SP70 in the serum of NSCLC patients,which suggested thai SP70 might be a potential valuable biomarker for the diagnosis of NSCLC.
